Yoshiyama Annie 4

4 · Allogene Therapeutics, Inc. · Filed Apr 23, 2026

AI-generated summary of this filing

Updated Apr 23, 2026

Allogene (ALLO) SVP Finance Annie Yoshiyama Sells 9,586 Shares

What Happened

Annie Yoshiyama, Senior Vice President, Finance at Allogene Therapeutics (ALLO), reported the sale of 9,586 shares on April 21, 2026. The reported weighted-average price was $2.31, for proceeds of about $22,144. The filing identifies this as a sell-to-cover to satisfy tax withholding tied to the vesting of restricted stock units (RSUs), not a discretionary sale.

Key Details

Transaction date: April 21, 2026; Form 4 filed April 23, 2026 (appears timely).
Reported price: weighted average $2.31; shares sold in multiple trades from $2.31 to $2.33.
Shares sold: 9,586; reported proceeds ≈ $22,144.
Reason: Sell-to-cover to satisfy tax withholding on vested RSUs (mandated under issuer's equity plan).
Shares owned after transaction: not specified in the provided filing summary.
Related note: filing footnote indicates inclusion of 3,781 shares acquired March 15, 2026 via employee stock purchase plan (ESPP).

Context

Sell-to-cover transactions are routine tax-withholding actions when RSUs vest and typically do not reflect an insider’s discretionary decision about the company’s prospects.
The filing shows a straightforward tax-withholding sale (transaction code S with explanatory footnote), not an options exercise, gift, or a strategic open-market purchase.

Form 4

Period: 2026-04-21

SVP, Finance

Transactions

Footnotes (3)

[F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.31 to $2.33, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
[F3]Includes 3,781 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.

Signature

/s/Earl Douglas, Attorney-in-Fact|2026-04-23

1 file